A Cohort Study of Patients Treated With Brachytherapy for Selected Desmoid Patients in Gardner Syndrome
The purpose of this study is to assess the long-term outcome in a cohort of Gardner-Syndrome patients receiving prophylaxis and treatment for intestinal and non-intestinal tumors.
|Study Design:||Observational Model: Cohort
Time Perspective: Retrospective
|Official Title:||In Modern Era, Recurrent Desmoids Determine Outcome in Patients With Gardner Syndrome: A Cohort Study of Three Generations of an Adenomatous Polyposis Coli (APC-) Mutation-Positive Family Across 30 Years|
- mortality [ Time Frame: 1978-2010 (as long as patients live) ] [ Designated as safety issue: No ]
- incidence of colorectal carcinoma [ Time Frame: 1978-2010 (entire patient life) ] [ Designated as safety issue: No ]
- Incidence of desmoid tumors [ Time Frame: 1978-2010 (entire patient life) ] [ Designated as safety issue: No ]
|Study Start Date:||January 1978|
|Study Completion Date:||December 2010|
|Primary Completion Date:||December 2010 (Final data collection date for primary outcome measure)|
Since 1978, we have been following a family of 105 descendants with Gardner Syndrome (GS). Mutation carriers were screened by endoscopy, and colorectal resection was performed upon pending malignancy. Resectable desmoid tumors were excised, whereas large tumors of the abdominal wall were treated by a combination of brachytherapy (BT) and radiotherapy (RT). Outcome was analyzed with respect to length of tumor-free survival, and morbidity from surgery or radiotherapy. Results: 37 of 105 family members have GS. Preventive colorectal resections were performed in 16 patients (15%), with one death due to subsequent gastric cancer. In 4 patients who denied screening endoscopy, invasive tumors of the colon (3 patients) and stomach (one patient each) developed. Of 33 desmoid tumors, 10 (30%) were located in the mesentery, 17 (52%) in the abdominal wall, and 6 (18%) in extra-abdominal sites. Excision of 12 desmoids was performed in 8 patients (36%), and 4 were treated by a combination of BT and RT. Following BT/RT, all patients showed full or partial remission.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01286662
|Principal Investigator:||Matthias Turina, MD PhD||Triemli Hospital|
|Study Director:||Hans P Simmen, MD||University of Zurich Hospital|